Puravankara Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 5, 2025, 5:09 pm

Quick Insight

Puravankara Ltd, a key player in the Construction & Contracting industry, currently trades at a price of 281 with a MarketCap of 6,659 Cr. Despite a P/E ratio not provided, the company shows a ROE of 9.99% and ROCE of 6.06%, indicating moderate profitability. Operating profit margin stands at 13%, while the Net Profit is -183 Cr, suggesting potential challenges. With reserves at 1,612 Cr and significant borrowings of ₹4,332 Cr, the company's financial structure warrants scrutiny. A high P/BV ratio of 3.37x and low ICR of 0.66x may raise concerns about valuation and debt servicing capabilities, respectively. In conclusion, investors should closely monitor Puravankara's financial health and operational efficiency to make informed decisions.

Competitors of Puravankara Ltd

All Competitor Stocks of Puravankara Ltd

Quarterly Result

Last Updated: August 20, 2025, 4:55 am

Below is a detailed analysis of the quarterly data for Puravankara Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 524.00 Cr.. The value appears to be declining and may need further review. It has decreased from 542.00 Cr. (Mar 2025) to 524.00 Cr., marking a decrease of 18.00 Cr..
• For Expenses, as of Jun 2025, the value is 458.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 511.00 Cr. (Mar 2025) to 458.00 Cr., marking a decrease of 53.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 67.00 Cr.. The value appears strong and on an upward trend. It has increased from 30.00 Cr. (Mar 2025) to 67.00 Cr., marking an increase of 37.00 Cr..
• For OPM %, as of Jun 2025, the value is 13.00%. The value appears strong and on an upward trend. It has increased from 6.00% (Mar 2025) to 13.00%, marking an increase of 7.00%.
• For Other Income, as of Jun 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 22.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 8.00 Cr..
• For Interest, as of Jun 2025, the value is 161.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 152.00 Cr. (Mar 2025) to 161.00 Cr., marking an increase of 9.00 Cr..
• For Depreciation, as of Jun 2025, the value is 10.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 11.00 Cr. (Mar 2025) to 10.00 Cr., marking a decrease of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is -90.00 Cr.. The value appears strong and on an upward trend. It has increased from -111.00 Cr. (Mar 2025) to -90.00 Cr., marking an increase of 21.00 Cr..
• For Tax %, as of Jun 2025, the value is -24.00%. The value appears to be improving (decreasing) as expected. It has decreased from -21.00% (Mar 2025) to -24.00%, marking a decrease of 3.00%.
• For Net Profit, as of Jun 2025, the value is -69.00 Cr.. The value appears strong and on an upward trend. It has increased from -88.00 Cr. (Mar 2025) to -69.00 Cr., marking an increase of 19.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is -2.85. The value appears strong and on an upward trend. It has increased from -3.62 (Mar 2025) to -2.85, marking an increase of 0.77.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 23, 2025, 2:13 pm

Growth

Last Updated: September 5, 2025, 12:45 pm

Balance Sheet

Last Updated: August 11, 2025, 2:36 pm

Below is a detailed analysis of the balance sheet data for Puravankara Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 119.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 119.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,612.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,765.00 Cr. (Mar 2024) to 1,612.00 Cr., marking a decrease of 153.00 Cr..
• For Borrowings, as of Mar 2025, the value is 4,332.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 3,325.00 Cr. (Mar 2024) to 4,332.00 Cr., marking an increase of 1,007.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 8,183.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,518.00 Cr. (Mar 2024) to 8,183.00 Cr., marking an increase of 1,665.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 14,245.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11,727.00 Cr. (Mar 2024) to 14,245.00 Cr., marking an increase of 2,518.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 232.00 Cr.. The value appears strong and on an upward trend. It has increased from 163.00 Cr. (Mar 2024) to 232.00 Cr., marking an increase of 69.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 2.00 Cr..
• For Investments, as of Mar 2025, the value is 40.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Mar 2024) to 40.00 Cr., marking an increase of 4.00 Cr..
• For Other Assets, as of Mar 2025, the value is 13,974.00 Cr.. The value appears strong and on an upward trend. It has increased from 11,526.00 Cr. (Mar 2024) to 13,974.00 Cr., marking an increase of 2,448.00 Cr..
• For Total Assets, as of Mar 2025, the value is 14,245.00 Cr.. The value appears strong and on an upward trend. It has increased from 11,727.00 Cr. (Mar 2024) to 14,245.00 Cr., marking an increase of 2,518.00 Cr..

However, the Borrowings (4,332.00 Cr.) are higher than the Reserves (1,612.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Puravankara Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -7.59. This value is below the healthy minimum of 5. It has decreased from 1.78 (Mar 24) to -7.59, marking a decrease of 9.37.
• For Diluted EPS (Rs.), as of Mar 25, the value is -7.52. This value is below the healthy minimum of 5. It has decreased from 1.77 (Mar 24) to -7.52, marking a decrease of 9.29.
• For Cash EPS (Rs.), as of Mar 25, the value is -6.50. This value is below the healthy minimum of 3. It has decreased from 3.25 (Mar 24) to -6.50, marking a decrease of 9.75.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 73.19. It has decreased from 79.67 (Mar 24) to 73.19, marking a decrease of 6.48.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 73.19. It has decreased from 79.67 (Mar 24) to 73.19, marking a decrease of 6.48.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 84.91. It has decreased from 92.14 (Mar 24) to 84.91, marking a decrease of 7.23.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 15.62. This value is within the healthy range. It has decreased from 22.67 (Mar 24) to 15.62, marking a decrease of 7.05.
• For PBIT / Share (Rs.), as of Mar 25, the value is 14.15. This value is within the healthy range. It has decreased from 21.49 (Mar 24) to 14.15, marking a decrease of 7.34.
• For PBT / Share (Rs.), as of Mar 25, the value is -9.21. This value is below the healthy minimum of 0. It has decreased from 3.18 (Mar 24) to -9.21, marking a decrease of 12.39.
• For Net Profit / Share (Rs.), as of Mar 25, the value is -7.97. This value is below the healthy minimum of 2. It has decreased from 2.07 (Mar 24) to -7.97, marking a decrease of 10.04.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -7.58. This value is below the healthy minimum of 2. It has decreased from 1.78 (Mar 24) to -7.58, marking a decrease of 9.36.
• For PBDIT Margin (%), as of Mar 25, the value is 18.39. This value is within the healthy range. It has decreased from 24.60 (Mar 24) to 18.39, marking a decrease of 6.21.
• For PBIT Margin (%), as of Mar 25, the value is 16.66. This value is within the healthy range. It has decreased from 23.31 (Mar 24) to 16.66, marking a decrease of 6.65.
• For PBT Margin (%), as of Mar 25, the value is -10.85. This value is below the healthy minimum of 10. It has decreased from 3.44 (Mar 24) to -10.85, marking a decrease of 14.29.
• For Net Profit Margin (%), as of Mar 25, the value is -9.39. This value is below the healthy minimum of 5. It has decreased from 2.24 (Mar 24) to -9.39, marking a decrease of 11.63.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is -8.93. This value is below the healthy minimum of 8. It has decreased from 1.93 (Mar 24) to -8.93, marking a decrease of 10.86.
• For Return on Networth / Equity (%), as of Mar 25, the value is -10.36. This value is below the healthy minimum of 15. It has decreased from 2.24 (Mar 24) to -10.36, marking a decrease of 12.60.
• For Return on Capital Employeed (%), as of Mar 25, the value is 17.58. This value is within the healthy range. It has decreased from 20.30 (Mar 24) to 17.58, marking a decrease of 2.72.
• For Return On Assets (%), as of Mar 25, the value is -1.26. This value is below the healthy minimum of 5. It has decreased from 0.36 (Mar 24) to -1.26, marking a decrease of 1.62.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.30 (Mar 24) to 0.06, marking a decrease of 0.24.
• For Total Debt / Equity (X), as of Mar 25, the value is 2.48. This value exceeds the healthy maximum of 1. It has increased from 1.74 (Mar 24) to 2.48, marking an increase of 0.74.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.15. It has decreased from 0.20 (Mar 24) to 0.15, marking a decrease of 0.05.
• For Current Ratio (X), as of Mar 25, the value is 1.05. This value is below the healthy minimum of 1.5. It has decreased from 1.12 (Mar 24) to 1.05, marking a decrease of 0.07.
• For Quick Ratio (X), as of Mar 25, the value is 0.18. This value is below the healthy minimum of 1. It has decreased from 0.20 (Mar 24) to 0.18, marking a decrease of 0.02.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 0.03, marking an increase of 0.03.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 353.52 (Mar 24) to 0.00, marking a decrease of 353.52.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 212.48 (Mar 24) to 0.00, marking a decrease of 212.48.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -253.52 (Mar 24) to 0.00, marking an increase of 253.52.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -112.48 (Mar 24) to 0.00, marking an increase of 112.48.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 3. It has decreased from 1.24 (Mar 24) to 0.66, marking a decrease of 0.58.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 3. It has decreased from 1.11 (Mar 24) to 0.65, marking a decrease of 0.46.
• For Enterprise Value (Cr.), as of Mar 25, the value is 9,420.43. It has increased from 7,334.08 (Mar 24) to 9,420.43, marking an increase of 2,086.35.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.68. This value exceeds the healthy maximum of 3. It has increased from 3.36 (Mar 24) to 4.68, marking an increase of 1.32.
• For EV / EBITDA (X), as of Mar 25, the value is 25.43. This value exceeds the healthy maximum of 15. It has increased from 13.64 (Mar 24) to 25.43, marking an increase of 11.79.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.91. This value is within the healthy range. It has increased from 2.28 (Mar 24) to 2.91, marking an increase of 0.63.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has increased from -253.52 (Mar 24) to 0.00, marking an increase of 253.52.
• For Price / BV (X), as of Mar 25, the value is 3.37. This value exceeds the healthy maximum of 3. It has increased from 2.64 (Mar 24) to 3.37, marking an increase of 0.73.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.91. This value is within the healthy range. It has increased from 2.28 (Mar 24) to 2.91, marking an increase of 0.63.
• For EarningsYield, as of Mar 25, the value is -0.03. This value is below the healthy minimum of 5. It has decreased from 0.01 (Mar 24) to -0.03, marking a decrease of 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness